News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bayer AG (BAY.F) Halts Study of Hemophilia Therapy BAY 86-6150 Due to Safety Concerns



5/6/2013 8:37:54 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Bayer said its HealthCare division stopped a Phase II/III study testing its experimental treatment BAY 86-6150 on certain haemophilia A and B patients due to safety concerns.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at News Release
Read at News Release


comments powered by Disqus
Bayer AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES